Oslo, 15 September 2014: With reference to the announcement 9 September Serodus ASA (Oslo Axess: SER), today will announce more details from the SER100 clinical study in patients with systolic hypertension.

The primary objective of the study was to demonstrate if 10 mg SER100 given twice daily for two consecutive days by subcutaneous injections, was safe and well tolerated. No serious adverse events, no drop-outs and no differences in tolerability between placebo and SER100 were observed. All events reported were mild and classified by the investigators as "probably related" to the treatment.

The secondary objective was to demonstrate if SER100 decrease the systolic blood pressure compared to placebo. After administration of SER100 the systolic blood pressure gradually decreased reaching a maximum effect after 3-5 hours. In all patients the average decrease was 12 mmHg with a p value of 0.005.

The detailed results will be presented at the capital markets day today, 15 September, 2 pm at Hotel Continental, Oslo, Norway. Presentations from the event will be published on the company website (www.serodus.com) after the event.

For questions contact:

Tore Kvam, CFO, IR, Serodus : + 47 959 34 199, e-mail tore.kvam@serodus.com

Eva Steiness, CEO, Serodus : tel +45 2226 5687, e-maileva.steiness@serodus.com

distributed by